nach oben

Supportive Care in Cancer

Erschienen in:

01.01.2005 | Short Communication

Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa)

verfasst von: Daniel T. Milton, Mark G. Kris, Jorge E. Gomez, Marc B. Feinstein

Erschienen in: Supportive Care in Cancer | Ausgabe 1/2005

Einloggen, um Zugang zu erhalten

Abstract

Bronchorrhea is a condition in which voluminous sputum is produced daily, typically seen with bronchioloalveolar cell carcinoma (BAC). Unless the underlying cancer can be controlled, bronchorrhea causes substantial symptomatic distress. We report two cases of bronchorrhea associated with advanced BAC successfully treated with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib. Prompt resolution of these patients’ bronchorrhea, dyspnea, and supplemental oxygen requirements are detailed. Given the limited success of alternative interventions, a trial of gefitinib should be considered for patients with bronchorrhea secondary to BAC.

Chang GC, Yang TY, Wang NS, Huang CM, Chiang CD (2003) Successful treatment of multifocal bronchioloalveolar cell carcinoma with ZD1839 (Iressa) in two patients. J Formos Med Assoc 102:407–411PubMed

Ebright MI, Zakowski MF, Martin J, Venkatraman ES, Miller VA, Bains MS, Downey RJ, Korst RJ, Kris MG, Rusch VW (2002) Clinical pattern and pathological stage but not histological features predict outcomes for bronchioloalveolar carcinoma (BAC). Ann Thorac Surg 74:1640–1646CrossRefPubMed

Homma S, Kawabata M, Kishi K, Tsuboi E, Narui K, Nakatani T, Nakata K (1999) Successful treatment of refractory bronchorrhea by inhaled indomethacin in two patients with bronchioloalveolar carcinoma. Chest 115:1465–1468CrossRefPubMed

Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 290:2149–2158CrossRefPubMed

Lopez-Vidriero M, Charman J, Keal E, Reid L (1975) Bronchorrhea. Thorax 30:624–630PubMed

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129–2139CrossRefPubMed

Miller VA, Kris MG, Shah N, Patel J, Azzoli CG, Gomez J, Krug LM, Pao W, Rizvi NA, Pizzo B, Tyson L, Venkatraman ES, Ben-Porat L, Memoli N, Zakowski MF, Rusch VM, Heelan R (2004) Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small cell lung cancer. J Clin Oncol 22:1103–1109CrossRefPubMed

Nadel JA (2001) Role of epidermal growth factor receptor activation in regulating mucin synthesis. Respir Res 2:85–89CrossRefPubMed

Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500CrossRefPubMed

10.

Suga T, Sugiyama Y, Fujii T, Kitamura S (1994) Bronchioloalveolar carcinoma with bronchorrhea treated with erythromycin. Eur Respir J 7:2249–2251CrossRefPubMed

11.

Takao M, Inoue K, Watanabe F, Onoda K, Shimono T, Shimpo H, Yada I (2003) Successful treatment of persistent bronchorrhea by gefitinib in a case with recurrent bronchioloalveolar carcinoma: a case report. World J Surg Oncol 1:8–11CrossRefPubMed

12.

Yano S, Kanematsu T, Miki T, Aono Y, Azuma M, Yamamoto A, Uehara H, Sone S (2003) A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (“Iressa”). Cancer Sci 94:453–458PubMed

Titel: Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa)
verfasst von: Daniel T. Milton
Mark G. Kris
Jorge E. Gomez
Marc B. Feinstein
Publikationsdatum: 01.01.2005
Verlag: Springer-Verlag
Erschienen in: Supportive Care in Cancer / Ausgabe 1/2005
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-004-0717-z

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa)

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2005

Current practice and knowledge of oral care for cancer patients: a survey of supportive health care providers

Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis

Society News January 2005

Forthcoming Meetings January 2005

Quality of life in long-term childhood cancer survivors and the relation of late effects and subjective well-being

Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: preliminary results and suggestions for future study designs

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie